Immuno-oxidative biomarkers and histopathological evaluation of heart and spleen tissues in doxorubicin- and cisplatin-induced toxicity in male albino rats
Open Access
- 10 October 2026
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 31708
Abstract
Doxorubicin (DOX) and cisplatin (CIS) are extensively used chemotherapeutic drugs, but their clinical use is hindered by systemic and organ-specific toxicities. This study comparatively evaluated the oxidative, inflammatory, hematological, immune, and tissue responses induced by DOX and CIS administered at the same dose. Adult male albino rats were randomly allocated into control and chemotherapy-treated groups. The chemotherapy groups received a single intraperitoneal injection of DOX or CIS (7.5 mg/kg). Serum oxidative stress markers (malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH)), inflammatory markers (tumor necrosis factor-alpha, interleukin-6, and myeloperoxidase), lactate dehydrogenase (LDH), troponin T, immunoglobulins (IgG and IgM), and hematological parameters were assessed. Cardiac and splenic tissues were evaluated for MDA, SOD, Nuclear factor kappa B (NF-κB), and caspase-3, together with histopathological examination and scoring. Both DOX and CIS caused anemia, leukocyte imbalance, thrombocytosis, and increased IgG and IgM, with more severe effects in DOX. Both agents also induced systemic oxidative stress, inflammation, and increased LDH and troponin T levels. In cardiac and splenic tissues, these treatments were associated with increased MDA, NF-κB, and caspase-3 levels, with reduced SOD activity. Histopathological examination and scoring revealed myocardial degeneration, vacuolation, necrosis, and inflammatory infiltration, as well as splenic white pulp depletion and disruption of the red–white pulp boundaries, with more pronounced damage observed in the DOX group. DOX and CIS induced systemic and tissue oxidative, inflammatory, hematological, and apoptotic disturbances, supporting an oxidative stress–NF-κB–apoptosis pathway in cardiac and splenic toxicity.Keywords
This publication has 75 references indexed in Scilit:
- Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar ratsJournal of Molecular Histology, 2026
- Empagliflozin mitigates doxorubicin-induced hepatotoxicity by reducing inflammation, oxidative stress, and apoptosis in male NMRI miceMedical Oncology, 2025
- Fenofibrate attenuates doxorubicin-induced cardiotoxicity in patients with breast cancer: a randomized controlled trialNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Possible pathogenic mechanisms for doxorubicin‐induced splenic atrophy in a human breast cancer xenograft mouse modelJournal of Applied Toxicology, 2024
- An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: characteristics, common molecular mechanisms, and current clinical managementClinical and Experimental Nephrology, 2024
- Edaravone and obeticholic acid protect against cisplatin-induced heart toxicity by suppressing oxidative stress and inflammation and modulating Nrf2, TLR4/p38MAPK, and JAK1/STAT3/NF-κB signalsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Exploring the cardioprotective effects of canagliflozin against cisplatin‐induced cardiotoxicity: Role of iNOS/NF‐κB, Nrf2, and Bax/cytochrome C/Bcl‐2 signalsJournal of Biochemical and Molecular Toxicology, 2023
- The cardiosplenic axis: the prognostic role of the spleen in heart failureHeart Failure Reviews, 2022
- Inflammation – Cause or Consequence of Heart Failure or Both?Current Heart Failure Reports, 2017
- Concurrent evolution of cancer cachexia and heart failure: bilateral effects existJournal of Cachexia, Sarcopenia and Muscle, 2014